Imunon (NASDAQ: IMNN) boosts at-the-market stock program to $17M

Q: How large is Imunon’s at-the-market stock offering program now?

Imunon’s at-the-market program now covers up to $17,000,000 of common stock. The company had previously registered $10,000,000 and has added a further $7,000,000 through the new prospectus supplement filed on March 23, 2026.

Q: How much stock has Imunon (IMNN) already sold under the ATM agreement?

Imunon has already sold an aggregate of $4,797,848 of common stock through H.C. Wainwright & Co. under the at-the-market sales agreement, prior to the March 23, 2026 prospectus supplement expanding the total amount that can be offered.

Q: What legal opinion is included with Imunon’s updated ATM registration?

The filing includes an opinion from Thompson Hine LLP as Exhibit 5.1 regarding the legality of the shares issuable under the sales agreement and covered by the prospectus supplement, along with a related consent filed as Exhibit 23.1.

Q: What type of securities is Imunon (IMNN) registering in this update?

Imunon is registering additional shares of its common stock , par value $0.01 per share. These shares are issuable from time to time under the existing at-the-market offering agreement with H.C. Wainwright & Co. as sales agent or principal.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Imunon, Inc. filed a prospectus supplement to register an additional $7,000,000 of common stock under its at-the-market offering program with H.C. Wainwright & Co.

This increases the aggregate amount covered by the program to $17,000,000 of shares. Before this update, the company had already sold $4,797,848 of common stock through the sales agent under the existing agreement.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

03/23/2026 - 04:16 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2026

IMUNON, INC.

(Exact name of registrant as specified in its Charter)

Delaware

001-15911

52-1256615

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

997 Lenox Drive, Suite 100, Lawrenceville, NJ		08648-2311
(Address of principal executive offices)		(Zip Code)

(609) 896-9100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		IMNN		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 23, 2026, Imunon, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) to register an additional $7,000,000 of shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), issuable pursuant to the At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024 (as amended, the “Sales Agreement”), by and between the Company and H.C. Wainwright & Co., LLC, as sales agent or principal (the “Sales Agent”). The Company previously registered the offer and sale of up to $10,000,000 of shares of Common Stock through the Sales Agent under the Sales Agreement. Accordingly, the Prospectus Supplement covers an aggregate of $17,000,000 of Shares. Of such amount, prior to the date hereof, the Company has sold an aggregate of $4,797,848 of shares of Common Stock through the Sales Agent under the Sales Agreement. An opinion regarding the legality of the Shares issuable under the Sales Agreement and covered by the Prospectus Supplement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
5.1		Opinion of Thompson Hine LLP.
23.1		Consent of Thompson Hine LLP (included in Exhibit 5.1).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMUNON, INC.

Dated: March 23, 2026	By:	/s/ Susan Eylward
		Susan Eylward
		General Counsel and Corporate Secretary

Source: View Original Filing on SEC EDGAR

FAQ

What did Imunon (IMNN) announce in this 8-K filing?

Imunon announced it filed a prospectus supplement to register an additional $7,000,000 of common stock under its at-the-market offering agreement, expanding the total program size to $17,000,000 in shares that may be issued through H.C. Wainwright & Co.

How large is Imunon’s at-the-market stock offering program now?

Imunon’s at-the-market program now covers up to $17,000,000 of common stock. The company had previously registered $10,000,000 and has added a further $7,000,000 through the new prospectus supplement filed on March 23, 2026.

How much stock has Imunon (IMNN) already sold under the ATM agreement?

Imunon has already sold an aggregate of $4,797,848 of common stock through H.C. Wainwright & Co. under the at-the-market sales agreement, prior to the March 23, 2026 prospectus supplement expanding the total amount that can be offered.

Who is the sales agent for Imunon’s at-the-market offering?

H.C. Wainwright & Co., LLC acts as Imunon’s sales agent or principal under the at-the-market offering agreement. The agreement, originally dated May 25, 2022, was amended on May 15, 2024 and continues to govern these common stock issuances.

What legal opinion is included with Imunon’s updated ATM registration?

The filing includes an opinion from Thompson Hine LLP as Exhibit 5.1 regarding the legality of the shares issuable under the sales agreement and covered by the prospectus supplement, along with a related consent filed as Exhibit 23.1.

What type of securities is Imunon (IMNN) registering in this update?

Imunon is registering additional shares of its common stock, par value $0.01 per share. These shares are issuable from time to time under the existing at-the-market offering agreement with H.C. Wainwright & Co. as sales agent or principal.

Filing Exhibits & Attachments

6 documents